Informationen:
Fehler:
ID
33443
Beschreibung
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression; ODM derived from: https://clinicaltrials.gov/show/NCT02431169
Link
https://clinicaltrials.gov/show/NCT02431169
Stichworte
Versionen (1)
- 09.12.18 09.12.18 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
9. Dezember 2018
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Carcinoma, Non-Small-Cell-Lung NCT02431169
Eligibility Carcinoma, Non-Small-Cell-Lung NCT02431169
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Carcinoma, Non-Small-Cell-Lung NCT02431169
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
LUNG CANCER ADENOCARCINOMA METASTATIC TNM clinical staging
Item
diagnosis of metastatic stage iiib/iv lung adenocarcinoma
boolean
C0746071 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,2])
Epidermal Growth Factor Receptor Mutation | EGFR exon 19 deletion | EGFR Exon 21 L858R Mutation
Item
presence of known sensitizing mutations in egfr tk domain (exon 19 deletion and l858r)
boolean
C0034802 (UMLS CUI [1,1])
C0026882 (UMLS CUI [1,2])
C3889117 (UMLS CUI [2])
C3274204 (UMLS CUI [3])
C0026882 (UMLS CUI [1,2])
C3889117 (UMLS CUI [2])
C3274204 (UMLS CUI [3])
Absence Epidermal Growth Factor Receptor Mutation Resistant | EGFR T790M
Item
absence of known resistant mutations in the egfr tk domain (t790m)
boolean
C0332197 (UMLS CUI [1,1])
C0034802 (UMLS CUI [1,2])
C0026882 (UMLS CUI [1,3])
C0332325 (UMLS CUI [1,4])
C3274192 (UMLS CUI [2])
C0034802 (UMLS CUI [1,2])
C0026882 (UMLS CUI [1,3])
C0332325 (UMLS CUI [1,4])
C3274192 (UMLS CUI [2])
Consent Clinical Trial Specified
Item
consented to hrpo# 201305031 ("tissue and blood acquisition for genomic analysis and collection of health information from patients with thoracic malignancies, suspected thoracic malignancies, or mesothelioma")
boolean
C1511481 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C0205369 (UMLS CUI [1,3])
C0008976 (UMLS CUI [1,2])
C0205369 (UMLS CUI [1,3])
Systemic therapy Malignant Neoplasms
Item
up to one prior line of systemic treatment for this malignancy
boolean
C1515119 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,2])
Absence Localized Therapy Biopsy site
Item
no prior localized therapy to the biopsy site
boolean
C0332197 (UMLS CUI [1,1])
C1517925 (UMLS CUI [1,2])
C1301128 (UMLS CUI [1,3])
C1517925 (UMLS CUI [1,2])
C1301128 (UMLS CUI [1,3])
Erlotinib Standard of Care Planned
Item
planned treatment with standard of care erlotinib
boolean
C1135135 (UMLS CUI [1,1])
C2936643 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
C2936643 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
Pregnancy Absent | Breast Feeding Absent
Item
not pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0332197 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Age
Item
at least 18 years of age
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
able to understand and willing to sign a written informed consent document
boolean
C0021430 (UMLS CUI [1])